Abstract:Concomitant use of medications for attention-deficit/hyperactivity disorder (ADHD), antipsychotics, mood-stabilizing anticonvulsants, and antidepressants is referred to as psychotropic polypharmacy. 1 Over the past 2 decades, psychotropic polypharmacy in youths increased, raising safety concerns. 2 -4 Our goal was to examine trends from 2015 to 2020 in psychotropic polypharmacy among youths aged 17 years or younger who were enrolled in Medicaid to identify temporal changes and characteristics associated with psychotropic polypharmacy. The cross-sectional study was approved by the University of Maryland institutional review board and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. Informed consent was waived because data were deidentified. This is a sequential, annual, cross-sectional study using Medicaid eligibility files and fee-for-service and managed care medical encounter claims from 2015 to 2020 from a single US state. For each annual cohort, we included youths who were 17 years or younger, had received at least 1 pharmacy claim for psychotropic medication, and had 90 days or more of continuous Medicaid enrollment. We created 4 mutually exclusive Medicaid eligibility groups in each annual cohort: (1) youths with low income, (2) youths enrolled in Children's Health Program (CHP), (3) youths in foster care, and (4) youths with disabilities. Additional information regarding the methods can be found in the eMethods in Supplement 1. Using the American Hospital Formulary Service Pharmacologic Therapeutic Classification System, we classified psychotropic medications into 6 therapeutic classes: antipsychotics, ADHD medications, mood-stabilizing anticonvulsants, antidepressants, anxiolytics, and sedatives. Use of 3 or more different psychotropic classes that overlapped for 90 consecutive days or longer in each study year defined psychotropic polypharmacy. 1 We allowed no more than a 15-day gap between prescription fills within the 90-day period. Annual psychotropic polypharmacy prevalence was defined as the proportion of youths who had at least 1 polypharmacy episode per 100 youths with any psychotropic use. A multivariable logistic regression model, using all study years, estimated the odds of psychotropic polypharmacy (dependent variable) among psychotropic users. Independent variables included study year (continuous), age, sex, race, region, Medicaid eligibility group, COVID-19, and mental health disorders. The race and ethnicity categories included in this study were American Indian, Asian, Black, Hispanic, Native Hawaiian, White, and all other races not listed in one of the predefined categories. Information regarding race and ethnicity was extracted from the Medicaid demographic summary file. We used generalized estimating equations for robust variance estimators to account for nonindependence of observations given that a youth may be in multiple study years. A supplemental analysis modeled categorical year (reference year, 2015) to identify which years contributed to significant psychotropic polypharmacy changes. Significance levels were set at P < .05 for 2-tailed tests. All analyses were performed using SAS Studio version 9.4 (SAS Institute). Data were analyzed from January to December 2023. Across all years, 126 972 unique youths met the inclusion criteria. Psychotropic polypharmacy prevalence among youths who used psychotropics increased from 2259 of 53 569 youths (4.2%) in 2015 to 2334 of 50 806 youths (4.6%) in 2020. The 2015 to 2020 increase in psychotropic polypharmacy prevalence was observed for those with Medicaid eligibility from foster care (414 of 3824 [10.8%] and 387 of 3420 [11.3%]), CHP (225 of 10 354 [2.2%] and 222 of 7974 [2.8%]), and being from a low-income household (648 of 30 222 [2.1%] and 883 of 31 172 [2.8%]) (Figure). The adjusted odds ratios (AORs) of psychotropic polypharmacy for the year was 1.04 (95% CI, 1.02-1.06), a 4% increase in the odds of psychotropic polypharmacy per year. The supplemental analysis revealed a significant increase in 2019 and 2020 relative to 2015. Psychotropic polypharmacy was significantly more likely among youths who were disabled (AOR, 3.68; 95% CI, 3.34-4.05) or in foster care (AOR, 3.31; 95% CI, 2.93-3.74) relative to youths in the low-income group. Individuals aged 10 to 14 years (AOR, 1.94; 95% CI, 1.80-2.10) and 15 to 17 years (AOR, 2.41; 95% CI, 2.22-2.61) had significantly higher odds of psychotropic polypharmacy than those who were younger than 10 years. Black individuals (AOR, 0.47; 95% CI, 0.43-0.51) or individuals who identified as other races (including individuals identifying as American Indian, Asian, Hispanic, or Pacific Islander, or other races) (AOR, 0.54; 95% CI, 0.50-0.59) had significantly lower odds of psychotropic polypharmacy than White individuals (Table). In this -Abstract Truncated-

PMH80 UTILIZATION PATTERN AND TREATMENT ADHERENCE WITH MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS AMONG PEDIATRIC PATIENTS WITH BIPOLAR DISORDER: A RETROSPECTIVE CLAIMS-BASED STUDY

Prescribing Patterns Of Antidepressants, Antipsychotics And Mood Stabilizers In Bipolar Patients Misdiagnosed With Major Depressive Disorder In China

Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study

Systematic Review and Network Meta-Analysis: Efficacy and Safety of Antipsychotics vs Antiepileptics or Lithium for Acute Mania in Children and Adolescents

Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability

A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths

Antipsychotic Medication Use In Medicaid-Insured Children Decreased Substantially Between 2008 And 2016

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials

Psychotropic medication use among adolescents participating in three randomized trials of DBT

Dosing levels of antipsychotics and mood stabilizers in bipolar disorder: A Nationwide cohort study on relapse risk and treatment safety

Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review

Analysis of the Status of Drug Treatment in 746 Inpatients with Early-Onset Schizophrenia in China: a Retrospective Study.

Treatment of bipolar depression: clinical practice vs. adherence to guidelines-data from a Bavarian drug surveillance project

Safety of Atypical Antipsychotics in a Child and Adolescent Inpatient Setting: A Naturalistic Study

Psychotropic Polypharmacy Among Youth Enrolled in Medicaid

Moderators of Treatment for Pediatric Bipolar Spectrum Disorders

Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018

Dosing of Mood Stabilizers for Bipolar Disorder Patients in the Research on Asian Psychotropic Prescription Patterns Consortium Study

Exploring real-world prescribing patterns for maintenance treatment in bipolar disorders: a focus on antidepressants and benzodiazepines

Exploring Patterns of Medication Usage in Affective Disorder Patients: A Comprehensive Investigation at a Psychiatry Outpatient Clinic of a Tertiary Care Hospital

Patterns of Psychotropic Prescribing Practices in Autistic Children and Adolescents: An Australian Perspective of Two Cohorts Five Years Apart